The test is for patients treated with isatuximab and will be used on Sebia’s Hydrasys 2 platform. Credit: Nephron.

In vitro diagnostic company Sebia has teamed up with French pharmaceutical firm Sanofi to develop a multiple myeloma diagnostic test.

The test will alleviate possible interference from Sanofi’s investigational antibody, isatuximab in Immunofixation Electrophoresis (IFE) tests.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Isatuximab is a monoclonal antibody targeting a specific epitope of CD38 capable of triggering action that promotes programmed tumour cell death and immunomodulatory activity.

Under the agreement, Sebia will develop an in vitro diagnostic (IVD) test and serve as supplier globally.

The agreement covers the growth of the Hydrashift 2 / 4 isatuximab IVD kit to be utilised in conjunction with Sebia’s proprietary IFE assay, Hydragel.

The companies, however, did not reveal the financial terms of the deal.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Specifically, the test is for patients treated with isatuximab for use on Sebia’s Hydrasys 2 platform.

Some multiple myeloma therapies using monoclonal antibodies can interfere with sufferers’ monoclonal proteins in IFE tests, which can lead to clinician errors in interpreting patient response to therapies.

Sebia CEO Jean-Marc Chermette said: “We are excited about partnering with Sanofi and further developing our Immunofixation range of products. The future Hydrashift 2 / 4 isatuximab test is in line with our strategy of developing innovative and advanced products for patient care.

“This development confirms Sebia’s commitment and strategic objective to remain the market leader in providing the most advanced diagnostic tools supporting multiple myeloma disease management.”

Sebia, in its press statement, notes that it will seek a CE Mark for the test in summer and then will pursue 510(k) clearance from the US Food and Drug Administration (FDA).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact